U.S. COMPANY FILING
BIOGEN INC. — Form 10-Q filed 2026-07-29
Filing text preview
Biogen's Q2 2026 10-Q reports the completion of the $5.3 billion Apellis acquisition on May 14, 2026, and a $100 million upfront payment for felzartamab rights in Greater China. Q2 revenue was $2.736 billion, net income $97.5 million, down sharply from $634.8 million a year ago. Cash and marketable securities fell to $1.3 billion, while total borrowings rose to $8.09 billion. The company recorded $153.2 million in restructuring charges and faces TECFIDERA patent revocation and generic competition.
This preview uses text already stored in ReportGem and does not fetch the document from object storage during SEO generation. Review the internal filing record and the official SEC source before relying on it.
Open filing record